Stockscreener 앱 받기
20.86
4.75%
-1.04
전일 마감가:
$21.90
열려 있는:
$21.88
하루 거래량:
399.22K
Relative Volume:
1.06
시가총액:
$861.13M
수익:
-
순이익/손실:
$-136.98M
주가수익비율:
-5.1891
EPS:
-4.02
순현금흐름:
$-126.63M
1주 성능:
+1.66%
1개월 성능:
-9.74%
6개월 성능:
-4.75%
1년 성능:
-14.79%
1일 변동 폭
$20.75
$22.40
1주일 범위
$19.56
$23.33
52주 변동 폭
$15.47
$29.71
Arrivent Biopharma Inc Stock (AVBP) Company Profile
명칭
Arrivent Biopharma Inc
전화
240-780-6356
주소
18 CAMPUS BLVD., NEWTOWN SQUARE
AVBP을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
AVBP
Arrivent Biopharma Inc
|
20.86 | 904.06M | 0 | -136.98M | -126.63M | -4.02 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.36 | 111.36B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
733.04 | 77.98B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
800.01 | 50.33B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
359.27 | 47.46B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
338.19 | 37.43B | 4.98B | 69.59M | 525.67M | 0.5197 |
Arrivent Biopharma Inc Stock (AVBP) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-10 | 개시 | BTIG Research | Buy |
| 2025-11-25 | 개시 | Truist | Buy |
| 2025-07-10 | 재개 | Goldman | Buy |
| 2025-03-20 | 개시 | B. Riley Securities | Buy |
| 2025-03-10 | 개시 | Guggenheim | Buy |
| 2024-07-22 | 개시 | Oppenheimer | Outperform |
| 2024-04-30 | 개시 | H.C. Wainwright | Buy |
| 2024-02-20 | 개시 | Citigroup | Buy |
| 2024-02-20 | 개시 | Goldman | Buy |
| 2024-02-20 | 개시 | Jefferies | Buy |
모두보기
Arrivent Biopharma Inc 주식(AVBP)의 최신 뉴스
Macro Review: Will OUSTW stock go up in YEAR2025 Risk Factors & Low Drawdown Investment Ideas - baoquankhu1.vn
Technical Analysis: Is ArriVent BioPharma Inc subject to activist investor interest2025 Earnings Impact & Advanced Swing Trade Entry Plans - baoquankhu1.vn
Entry Recap: Will SHIP outperform tech stocksQuarterly Portfolio Report & Free Reliable Trade Execution Plans - baoquankhu1.vn
ArriVent stock rating reiterated as Overweight by Cantor Fitzgerald - Investing.com Canada
(AVBP) and the Role of Price-Sensitive Allocations - Stock Traders Daily
ArriVent Therapeutics: Late-Stage Firmonertinib Data and Differentiated Profile Support Buy Rating and Upside Potential - TipRanks
ArriVent BioPharma, Inc. (NASDAQ:AVBP) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
ArriVent BioPharma (NASDAQ:AVBP) Stock Price Up 7.2%Should You Buy? - MarketBeat
Aug Drivers: Should you avoid Zura Bio Limited stock right nowEarnings Summary Report & Scalable Portfolio Growth Ideas - baoquankhu1.vn
Fast-Tracking the $537B Cancer Cure: How Accelerated Approvals Reshaping Oncology in 2026 - Benzinga
Fast-Tracking the $537B Cancer Cure: How Accelerated Approvals Reshaping Oncology in 2026 - Sahm
Aug Volume: Can ArriVent BioPharma Inc. stock attract ESG capital inflowsJuly 2025 Final Week & Short-Term Trading Opportunity Alerts - Улправда
Can ArriVent BioPharma Inc. stock attract ESG capital inflowsJuly 2025 Rallies & Entry Point Strategy Guides - Улправда
Will ArriVent BioPharma Inc. stock see insider buyingQuarterly Market Review & Fast Moving Stock Trade Plans - Улправда
Oppenheimer reiterates Outperform rating on ArriVent BioPharma stock By Investing.com - Investing.com Canada
ArriVent BioPharma (NASDAQ:AVBP) Stock Price Down 7.4%Here's What Happened - MarketBeat
Responsive Playbooks and the AVBP Inflection - Stock Traders Daily
ArriVent BioPharma: Its Leading Asset, Furmonertinib, Supports A Cautious Buy - Seeking Alpha
Firmonertinib Trial Aims to Crack a Long-Standing Lung Cancer Treatment Gap - MyChesCo
ArriVent BioPharma: A De-Risked Binary With Near-Term Catalysts (NASDAQ:AVBP) - Seeking Alpha
(AVBP) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
ArriVent BioPharma (NASDAQ:AVBP) Trading Down 3.2%What's Next? - MarketBeat
ArriVent doses first patient in pivotal phase 3 trial for lung cancer drug - Investing.com Australia
ArriVent Biopharma initiated with an Overweight at Cantor Fitzgerald - TipRanks
Cantor Fitzgerald initiates ArriVent BioPharma stock with Overweight rating By Investing.com - Investing.com Canada
Cantor Fitzgerald initiates ArriVent BioPharma stock with Overweight rating - Investing.com
ArriVent Biopharma announces first patient dosed in Phase 3 ALPACCA study - TipRanks
ArriVent BioPharma Begins Phase 3 Trial of Firmonertinib in Lung Cancer - marketscreener.com
ArriVent BioPharma Initiates Pivotal Phase 3 ALPACCA Study of Firmonertinib for First-Line Treatment of EGFR PACC Mutant NSCLC - Quiver Quantitative
ArriVent doses first patient in pivotal phase 3 trial for lung cancer drug By Investing.com - Investing.com South Africa
ArriVent Announces First Patient Dosed in Global Pivotal Phase 3 ALPACCA Trial Evaluating Firmonertinib for First-Line Treatment of EGFR PACC Mutant Non-Small Cell Lung Cancer - marketscreener.com
New lung cancer trial tests a daily chemo-free pill for rare mutation - Stock Titan
Investment Recap: Will ArriVent BioPharma Inc. stock benefit from AI adoptionLong Setup & Daily Profit Maximizing Tips - Улправда
Will ArriVent BioPharma Inc. stock benefit from AI adoptionQuarterly Portfolio Review & Free AI Powered Buy and Sell Recommendations - Улправда
ArriVent BioPharma, Inc. (NASDAQ:AVBP) Receives Average Recommendation of “Moderate Buy” from Analysts - Defense World
ArriVent BioPharma, Inc. (NASDAQ:AVBP) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Will ArriVent BioPharma Inc. stock pay special dividendsTrade Volume Summary & Low Drawdown Investment Strategies - ulpravda.ru
Will ArriVent BioPharma Inc. stock remain a Wall Street favorite2025 Technical Overview & Real-Time Buy Zone Alerts - Улправда
Why ArriVent BioPharma Inc. stock is recommended by analystsMarket Trend Summary & Weekly Breakout Watchlists - Улправда
ArriVent BioPharma (NASDAQ:AVBP) Stock Price Down 5.6%Here's What Happened - MarketBeat
Will ArriVent BioPharma Inc. stock deliver consistent dividendsJuly 2025 Price Swings & AI Forecasted Entry and Exit Points - Улправда
Immunotherapy Breakthroughs Turn Cold GI Tumors Hot as Market Tops $443B (2025-12-16) - Seeking Alpha
Squarepoint Ops LLC Grows Stock Position in ArriVent BioPharma, Inc. $AVBP - MarketBeat
Immunotherapy Breakthroughs Turn Cold GI Tumors Hot as Market Tops $443B - Newswire Canada
ArriVent BioPharma Earnings Notes - Trefis
ArriVent Biopharma initiated with a Buy at BTIG on firmonertinib potential - MSN
Fund 1 Investments LLC Acquires New Position in ArriVent BioPharma, Inc. $AVBP - MarketBeat
Why (AVBP) Price Action Is Critical for Tactical Trading - Stock Traders Daily
BTIG Research Begins Coverage on ArriVent BioPharma (NASDAQ:AVBP) - Defense World
ArriVent BioPharma Inc (AVBP) is looking forward to a strong quarter - setenews.com
ArriVent BioPharma (NASDAQ:AVBP) Coverage Initiated at BTIG Research - MarketBeat
Arrivent Biopharma Inc (AVBP) 재무 분석
매출
순이익
현금흐름
주당 순 이익
4.73%
0.92%
자본화:
|
볼륨(24시간):